What do systematic reviews say?

Antidepressants vs antipsychotics

The review found no eligible studies for this question.

• Pharmacological treatment for psychotic depression 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Antidepressants vs antipsychotics

The review found no eligible studies for this question.

• Pharmacological treatment for psychotic depression 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Antidepressants vs placebo

The review found no eligible studies for this question.

• Pharmacological treatment for psychotic depression 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Antidepressants vs placebo

The review found no eligible studies for this question.

• Pharmacological treatment for psychotic depression 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Antidepressants vs placebo

Antidepressant showed no clear difference in study dropouts at 6‐12 weeks compared with placebo (moderate certainty).

• Antidepressants for depression in adults with HIV infection 2018 · Cochrane Headline outcomes only
  RR 1.28 [0.91, 1.8]
  4 studies · 306 participants
  Moderate

Antidepressants vs placebo

• Antidepressants for depression in adults with HIV infection 2018 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 87 participants
  Very low

TCAs with predominantly SRI actions vs placebo

It is very uncertain whether TCAs with predominantly SRI actions changes treatment responseaClinical Global Impressions ‐ Improvement Scale… compared with placebo (very low certainty).

• Pharmacotherapy for trichotillomania 2021 · Cochrane Headline outcomes only
  RR 5.73 [0.36, 90.83]
  1 study · 16 participants
  Very low

Tricylic antidepressant vs placebo

• Pharmacological interventions for the treatment of depression in chronic obstructive pulmonary disease 2018 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 30 participants
  Very low

Tricylic antidepressant vs placebo

• Pharmacological interventions for the treatment of depression in chronic obstructive pulmonary disease 2018 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 30 participants
  Very low

Tricylic antidepressant vs placebo

• Pharmacological interventions for the treatment of depression in chronic obstructive pulmonary disease 2018 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 30 participants
  Very low

Tricylic antidepressant vs placebo

• Pharmacological interventions for the treatment of depression in chronic obstructive pulmonary disease 2018 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 30 participants
  Very low

Tricylic antidepressant vs placebo

• Pharmacological interventions for the treatment of depression in chronic obstructive pulmonary disease 2018 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 30 participants
  Very low

Tricylic antidepressant vs placebo

The review found no eligible studies for this question.

• Pharmacological interventions for the treatment of depression in chronic obstructive pulmonary disease 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Antidepressants vs placebo at 12 months' follow‐up

Antidepressant medication may leads to lower recurrence at 12 months compared with placebo at 12 months' follow‐up (low certainty).

• Continuation and maintenance treatments for depression in older people 2016 · Cochrane Headline outcomes only
  RR 0.67 [0.55, 0.82]
  3 studies · 247 participants
  Low

Antidepressants vs placebo at 12 months' follow‐up

Antidepressant medication showed no clear difference in overall drop‐out rates (excluding deaths) at 12 months compared with placebo at 12 months' follow‐up (low certainty).

• Continuation and maintenance treatments for depression in older people 2016 · Cochrane Headline outcomes only
  RR 1.48 [0.75, 2.92]
  1 study · 121 participants
  Low

Second generation antidepressant vs placebo medication

• Newer generation antidepressants for depressive disorders in children and adolescents 2012 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

Second generation antidepressant vs placebo medication

Second generation antidepressant probably leads to higher remission or response (as defined in trial) compared with placebo (by medication) (moderate certainty).

• Newer generation antidepressants for depressive disorders in children and adolescents 2012 · Cochrane Headline outcomes only
  RR 1.18 [1.08, 1.28]
  16 studies · 2924 participants
  Moderate

Second generation antidepressant vs placebo medication

Second generation antidepressant may leads to higher suicide‐related outcome compared with placebo (by medication) (low certainty).

• Newer generation antidepressants for depressive disorders in children and adolescents 2012 · Cochrane Headline outcomes only
  RR 1.58 [1.02, 2.45]
  17 studies · 3229 participants
  Low

Antidepressant plus antipsychotic vs placebo

It is very uncertain whether antidepressant plus antipsychotic changes overall dropouts compared with placebo (very low certainty).

• Pharmacological treatment for psychotic depression 2021 · Cochrane Headline outcomes only
  RR 0.75 [0.48, 1.18]
  2 studies · 148 participants
  Very low

Antidepressant plus antipsychotic vs placebo

The review found no eligible studies for this question.

• Pharmacological treatment for psychotic depression 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found